Cleveland Clinic researchers are testing a novel immunotherapy/cancer vaccine combination in patients with recurrent glioblastoma, in hopes of finding an effective treatment for a condition with poor survival outcomes and a shortage of viable therapeutic options.
A leading clinician-researcher profiles clinical trials of mechanistically diverse treatment strategies to combat glioblastoma. All four stem from Cleveland Clinic’s robust translational collaborations in this space.
An early use of laser interstitial thermal therapy followed by chemo-radiation has left a patient with WHO grade IV astrocytoma with no evidence of residual tumor or recurrence more than 6.5 years later.
A phase 2 trial demonstrates promising results in patients with glioblastoma who take SurVaxM, an immunotherapy vaccine that targets survivin.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Final results of a large trial show that a head-worn device delivering alternating electric fields significantly extends survival when added to temozolomide therapy. It’s the first progress against glioblastoma in a decade.
Ground-breaking research shows combining radiology, especially stereotactic radiosurgery, and targeted drugs significantly increases survival in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
Oncologists hope to extend survival of glioblastoma patients by combining cell checkpoint inhibitors with concurrent or adjuvant chemotherapy and radiation.
Cleveland Clinic researchers in brain metastases present updates at ASCO: Mutation status matters in patients with NSCLC and KPS isn’t the whole story in gastroesophageal cancer.
When conventional therapy failed a woman with a rare glioma, she sought re-treatment at Cleveland Clinic. Pulsed low-dose-rate radiation and anti-angiogenic therapy helped restore movement and speech.
Potentially good news for the 170,000+ people in the U.S. diagnosed each year with melanoma brain metastases. Study finds better outcomes when combining stereotactic radiosurgery with tumor molecular analysis.